

Article

Synthesis, NMR Characterization, and Antileukemic Activity of *N*-Nonanoylpiperazinyl-5 α -Androstane-3 α ,17 β -Diol A-Ring Derivatives

Donald Poirier ^{1,2,*}, Imad Raad ¹, Jenny Roy ¹ and René Maltais ¹

¹ Laboratory of Medicinal Chemistry, Endocrinology and Nephrology Unit, CHU de Québec—Research Center, Québec, QC G1V 4G2, Canada; imad.raad.1@ulaval.ca (I.R.); jenny.roy@crchudequebec.ulaval.ca (J.R.); rene.maltais@crchudequebec.ulaval.ca (R.M.)

² Department of Molecular Medicine, Faculty of Medicine, Université Laval, Québec, QC G1V 0A6, Canada

* Correspondence: donald.poirier@crchudequebec.ulaval.ca; Tel.: +1-418-654-2296

Abstract: The combination of an androstane-3,17-diol nucleus and a 2 β -*N*-alkylamidopiperazino sidechain is important for the anticancer activity of a new family of steroid derivatives. As the structure-activity relationship studies have so far been limited to the beta orientation of the substituent at position 2 of the steroid nucleus, a series of analogs (compounds 1–4) were synthesized to investigate the impact on biological activity of A-ring substitution. Nuclear magnetic resonance (NMR) analysis, especially using a series of 2D experiments, such as correlation spectroscopy (COSY), homonuclear Overhauser effect spectroscopy (NOESY), heteronuclear single-quantum correlation (HSQC), and heteronuclear multiple-bond correlation (HMBC) provided crucial information that was found essential in confirming the sidechain position and orientation of compounds 1–4. Assessment of their antiproliferative activity on leukemia HL-60 cells confirmed the best efficiency of the 2 β -sidechain/3 α -OH orientation (compound 1) compared to the other configurations tested (compounds 2–4).



Citation: Poirier, D.; Raad, I.; Roy, J.; Maltais, R. Synthesis, NMR Characterization, and Antileukemic Activity of *N*-Nonanoylpiperazinyl-5 α -Androstane-3 α ,17 β -Diol A-Ring Derivatives. *Magnetochemistry* **2021**, *7*, 3. <https://dx.doi.org/10.3390/magnetochemistry7010003>

Received: 28 November 2020

Accepted: 21 December 2020

Published: 23 December 2020

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Keywords: steroid; androstane; nuclear magnetic resonance; antileukemic agent; HL-60 cells

1. Introduction

Steroid derivatives with a *N*-substituted piperazino sidechain at position C2 β of 5 α -androstane-3 α ,17 β -diol showed antiproliferative activity on different cancer cell lines [1–6] and promising results were obtained with two representative candidates tested in mouse xenograft tumor models [6–8]. They were designed by combining two crucial elements: A steroid core and a lateral piperazino sidechain in A-ring (Figure 1A). Structure-activity relationship (SAR) studies have made it possible to optimize the composition of the sidechain added at position 2 β of the 5 α -androstane-3 α , 17 β -diol steroid nucleus [2–4], but the impact on the biological activity of the sidechain and hydroxyl group positioning on A-ring has never been studied. In fact, the work focused only on the 2 β -sidechain (R) and 3 α -OH orientations (compound 1; Figure 1B), i.e., the configuration most easily chemically accessible by the regioselective and stereoselective opening (aminolysis) of the 2 α ,3 α -steroidal epoxide [9–13]. Since the therapeutic target was not known for these aminosteroids, which precluded the use of molecular modeling, it was therefore crucial to extend the SAR study. To do this, it was necessary to obtain other derivatives with the same sidechain (*N*-nonanoylpiperazinyl), albeit in another orientation or position.

In addition to their chemical synthesis and biological evaluation, our challenge was to fully characterize the four steroid derivatives 1–4 by 1D and 2D nuclear magnetic resonance (NMR) experiments and to confirm both sidechain and OH orientations in A-ring.




Figure 1. (A) Representation of a new family of anticancer agents showing their crucial structural elements. Both sidechain and steroid core are needed to inhibit cancer cell proliferation. (B) New A-ring steroid derivatives 1–4 needed to extend the SAR study.

2. Results and Discussion

2.1. Chemical Synthesis of Compounds 1–4

Compounds **1** and **2** (2 β -sidechain/3 α -OH and 4 β -sidechain/3 α -OH) were obtained by an epoxide opening (Figure 2). We first generated the mixture of 2 α ,3 α and 3 α ,4 α -epoxides **5a** and **5b** (76:24) from the corresponding mixture of alkenes, which had been prepared from commercially available epiandrosterone by tosylation, elimination and reduction steps [3]. It is possible to perform a partial selective opening of 2 α ,3 α -epoxide *vs* 3 α ,4 α -epoxide using mild aminolysis conditions (2 equivalents of piperazine, ethylene glycol, 130 °C) [13], but we chose to use more severe aminolysis conditions (50 equivalents of piperazine, H₂O, 166 °C [14,15]) to generate a mixture of amino alcohols. In fact, from the four possible piperazine alcohols, the opening of such an epoxide mixture is known to give the compounds resulting from the two *trans*-diaxial openings in agreement with Barton's generalization [11,12,15]. Thus, opening 2 α ,3 α -epoxide led to compound **6a**, whereas opening 3 α ,4 α -epoxide led to compound **6b**. The amidation of the mixture of amines **6a** and **6b** with nonanoic acid, with *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HBTU) as coupling agent, and diisopropylethylamine (DIPEA) as base provided **1** and **2**, respectively, after separation by chromatography. The former had already been prepared from the opening of pure 2 α ,3 α -epoxide followed by amidation [2], but confirmation of the stereochemistry at positions 2 and 3 had not been performed by an NMR study and it was not possible to obtain a crystal to perform the X-ray analysis of compound **1**.




Figure 2. Synthesis of compounds **1** and **2**. Reagents and conditions: (a) Piperazine, H₂O, 166 °C; (b) Nonanoic acid, HBTU, diisopropylethylamine (DIPEA), dimethylformamide (DMF), room temperature; (c) Silica gel chromatography purification (18% and 9.9% of **1** and **2**, respectively, for 2 steps).

Compound **3** (2 α -sidechain/3 α -OH) was obtained in two steps from compound **1** (Figure 3). Swern's oxidation first gave the 3,17-diketone **7** in moderate yield. The presence of a carbonyl in position 3, the acidity of the proton in position 2, and the triethy-

amine(TEA) used in the Swern's reaction [16] favored the isomerization at carbon 2 (C2), which went from a 2 β -sidechain orientation (less stable; 60.1 kcal/mol) to 2 α (more stable; 59.0 kcal/mol). The α -configuration of the substituent at C2 position of compound 7 was determined by a homonuclear Overhauser effect (NOE) spectroscopy (NOESY) experiment showing a correlation between CH₃-19 and CH-2 β . In the next step, the two C3- and C17-carbonyls were stereoselectively reduced using NaBH₄ to obtain the desired compound 3. Considering the presence of the axial methyl-18 close to carbonyl-17, the reduction is highly stereoselective and produces the expected 17 β -OH [17]. The reduction of the carbonyl-3 proceeded by the less hindered β -steroid face and generated the 3 α -OH alcohol 3 as confirmed by the subsequent 2D NMR analysis of 3.




Figure 3. Synthesis of compounds 3. Reagents and conditions: (a) Oxalyl chloride, DMSO, triethylamine (Et₃N), CH₂Cl₂, −60 °C (44% of 7); (b) NaBH₄, MeOH/CH₂Cl₂ (9:1), 0 °C (22% of 3).

Finally, compound 4 (3 α -sidechain/2 β -OH) was also prepared by a stereoselective aminolysis according to the generalization of Barton [11,12], but using a key 2 β ,3 β -epoxide (Figure 4). In fact, the attack of piperazine takes place at position 3 [15] by the α -steroid face of epoxide 8 to generate the amino alcohol 9 resulting from the trans-diaxial opening. The amidation of the secondary amine of 9 with nonanoic acid, HBTU, and DIPEA thus provided compound 4.




Figure 4. Synthesis of compound 4. Reagents and conditions: (a) Piperazine, H₂O, 160 °C; (b) Nonanoic acid, HBTU, diisopropylamine (DIPEA), dimethylformamide (DMF), 0 °C, room temperature.

The yields for the synthesis of compounds 1–4 were low, but the quantities obtained were considered sufficient for characterization and biological evaluation, so they were not optimized. In the context of a previous study [2], compound 1 had been obtained with a 70% yield for the opening of the epoxide and an 82% yield for the amidation, leading to an overall 57% yield for the 2 steps. In this study, however, the fact that the two reactions were performed without purifying the intermediate compound, which may have contributed to the low overall yields of respectively 18%, 9.9% and 22% for compounds 1, 2, and 4. However, the 22% yield for compound 3 may be explained by an incomplete reduction of the two carbonyls and the formation of a mixture of monoketonic compounds (42%).


2.2. Nuclear Magnetic Resonance (NMR) Characterization

2.2.1. Assignments of Carbons and Protons

The assignment of NMR signals corresponding to the carbons and protons of aminosteroids 1–4 is an essential step before the characterization of the positioning and stereochemistry of the two A-ring substituents (Table 1). The signals of carbons 6–18 (B, C and D-rings) were easily assigned considering data from the literature [18–21]. From the J_{CH} correlations in the heteronuclear single-quantum correlation (HSQC) spectra we then identified the

signals of the corresponding protons. In addition, the chemical shifts (δ) of carbons 6–18 do not differ between compounds 1–4 since the modifications on the A-ring do not affect them. However, a slight difference of 1.2 ppm is observed for C-7 (34.0 ppm for **2** vs 32.8 ppm for **1**, **3**, and **4**). For the nonanoyl chain located on the piperazine ring, ^{13}C and ^1H NMR signals were also identical between the four compounds. Signals were assigned using HSQC (J_{CH}) and heteronuclear multiple-bond correlation (HMBC) (J_{CCH} and J_{CCCH}). Thus, in ^1H NMR, the CH_3 -9'' signal at 0.92 ppm, which is the only triplet among the three methyl signals, was linked to the 14.4 ppm signal in ^{13}C NMR. This later was next used to identify C-8'' (J_{HH} and J_{CCH}) and C-7'' (J_{CCCH}). Similarly, the identification of CH_2 -2'' at 2.38–2.40 ppm (shielded by the carbonyl) leads to C-2'' (J_{CH}), CH_2 -3'' (J_{HH}) and C-4'' (J_{CCCH}), this latter methylene with an identical δ to those of CH_2 -5'' and 6''. For the CH_2 of the piperazine nucleus, they appear as a broad multiplet at about 3.5 ppm for the protons near the amide group (CH_2 -3' and 5'), which correlate (J_{CH}) with two signals at around 43 and 47 ppm. For the neighboring protons of the amine group (CH_2 -2' and 6'), they appear in the form of two multiplets around 2.5–2.7 ppm in ^1H NMR, which correlate (J_{CH}) with two signals around 50.9–51.9 ppm in ^{13}C NMR for compounds **1**, **3**, and **4**, but 53.8 and 54.4 ppm for compound **2**. For this later, the C4 positioning of the sidechain (close to the substituted C-5) is responsible for this deshielding effect of about 3 ppm.

Having already identified the CH_3 -9'' and CH_3 -18, then the singlet between 0.86–1.11 ppm (^1H NMR) and the signal between 12.9–15.6 ppm (^{13}C NMR) corresponds to CH_3 -19 at the junction of rings A and B. From this signal, we observed four important correlations in the HMBC spectrum that make it possible to identify the carbons CH_2 -1, CH-5, CH-9, and C-10. The J_{CCH} correlation with C-10 (37.1–37.7 ppm for **1–4**) indicates that the positioning of the chain has little influence on the chemical shift. It is the same for CH-9 (56.3–57.4 ppm) identified by a J_{CCCH} correlation, but not for CH-5 (J_{CCCH} , 40.0–45.7 ppm). For the latter, the presence of the C4-sidechain (compound **2**) causes a significant deshielding effect (~5 ppm). The fourth J_{CCCH} correlation allows the identification of CH_2 -1 (34.0–36.9 ppm for **1–3** and 42.4 ppm for **4**), whose chemical shift is greatly affected (8 ppm) by the presence of a chain on C-3 α . For the assignment of the three remaining carbons (C2, C3 and C4), the significant deshielding effect for CH-OH (66.6–68.5 ppm) and CH-NR₁R₂ (63.0–70.5 ppm) in ^{13}C NMR should be noted, and is not the case with the CH_2 at C2 or C4 (26.6–36.5 ppm). The remaining CH_2 was thus easily identified since this is the last unassigned signal and because of the use of attached proton test (APT) and HSQC spectra (two separate signals for the two protons). For the two A-ring CHs, it is well known that a CH carrying an OH is more shielded (4.09–4.15 ppm) in ^1H NMR than that carrying an NR₁R₂ (1.90–2.40 ppm) and the HSQC spectra (J_{CH}) made it possible to discriminate the two CH. In the case of compound **1**, and contrary to the three other compounds, the 2-CH and 3-CH signals are identical in ^{13}C NMR.

Table 1. Chemical shifts (δ in ppm) and assignment of ^1H and ^{13}C from compounds 1–4 in CD_3OD .

C and H Assignment	1 (^1H) 2 β -Chain-	1 (^{13}C) -3 α -OH	2 (^1H) 4 β -Chain-	2 (^{13}C) -3 α -OH	3 (^1H) 2 α -Chain-	3 (^{13}C) -3 α -OH	4 (^1H) 3 α -Chain-	4 (^{13}C) -2 β -OH
CH ₂ -1	1.40/1.82	34.5	1.40/1.52	34.0	1.30/1.73	36.9	1.54/1.68	42.4
CH-2 or CH ₂ -2	2.40	66.5	1.90	26.9	2.24	63.0	4.09	68.5
CH-3	4.10	66.6	4.10	66.6	4.15	66.8	2.25	65.8
CH-4 or CH ₂ -4	1.35	34.2	2.34	70.5	1.55	36.5	1.42/1.82	26.6
CH-5	1.66	40.6	1.77	45.7	1.60	40.0	1.48	41.1
CH ₂ -6	1.30	29.0	1.40	29.2	1.30	28.9	1.28	29.2
CH ₂ -7	0.92/1.71	32.7	0.91/1.80	34.0	0.95/1.88	32.8	0.92/1.71	32.8
CH-8	1.42	36.6	1.40	37.0	1.45	36.6	1.46	36.5
CH-9	0.75	56.9	0.73	57.4	0.82	56.3	0.72	57.1
C-10	-	37.3	-	37.2	-	37.7	-	37.1
CH ₂ -11	1.38/1.62	21.8	1.33/1.58	21.1	1.38/1.70	21.6	1.33/1.60	21.7
CH ₂ -12	1.05/1.84	38.1	1.04/1.84	38.1	1.10/1.85	38.0	1.05/1.84	38.1
C-13	-	44.2	-	44.0	-	44.1	-	44.2
CH-14	0.95	52.4	0.93	52.4	1.00	52.4	0.96	52.4
CH ₂ -15	1.25/1.60	24.3	1.27/1.62	24.3	1.30/1.62	24.3	1.26/1.60	24.3
CH ₂ -16	1.46/1.98	30.6	1.45/1.98	30.6	1.50/2.00	30.6	1.47/1.98	30.6
CH-17	3.57	82.5	3.57	82.5	3.57	82.5	3.57	82.5
CH ₃ -18	0.74	11.7	0.74	11.6	0.75	11.7	0.74	11.7
CH ₃ -19	1.04	14.6	1.11	14.5	0.86	12.9	1.05	15.6
CH ₂ -2'/CH ₂ -6'	2.53/2.63	51.4/51.9	2.63/2.68	53.8/54.4	2.65/2.70	50.9/51.3	2.50/2.56	51.4/51.9
CH ₂ -3'/CH ₂ -5'	3.57	43.1/47.2	3.50/3.57	43.6/47.7	3.58	43.0/47.1	3.57	43.1/47.2
C-1''	-	174.1	-	174.1	-	174.1	-	174.0
CH ₂ -2''	2.40	34.0	2.38	34.0	2.40	34.0	2.40	34.0
CH ₂ -3''	1.61	26.6	1.61	26.6	1.62	26.6	1.61	26.6
CH ₂ -4''	1.34	30.3	1.34	30.3	1.36	30.3	1.35	30.3
CH ₂ -5''	1.34	30.5	1.34	30.5	1.36	30.5	1.35	30.5
CH ₂ -6''	1.34	30.5	1.34	30.4	1.36	30.4	1.35	30.4
CH ₂ -7''	1.34	33.0	1.34	33.0	1.36	33.0	1.33	33.0
CH ₂ -8''	1.34	23.7	1.34	23.7	1.35	23.7	1.33	23.7
CH ₂ -9''	0.92	14.4	0.92	14.4	0.92	14.4	0.92	14.5

¹ After a full assignment of all carbons (heteronuclear single-quantum correlation (HSQC), heteronuclear multiple-bond correlation (HMBC), correlation spectroscopy (COSY), homonuclear Overhauser effect spectroscopy (NOESY), and literature data), the chemical shift of each corresponding proton was obtained from the J_{CH} correlation observed in HSQC spectra. ^1H NMR, ^{13}C NMR, NOESY, COSY, HSQC, and HMBC spectra for compounds 1–4 are available in Supplementary Materials.

2.2.2. Positioning and Orientation of A-Ring Sidechain and OH

Compounds 1–4 differ only by the positioning and orientation of A-ring substituents, which were determined by a careful analysis of NMR data. For compound 1 (2 β -R/3 α -OH; Figure 5A), two J_{HH} correlations (COSY) between CH-2 and CH₂-1, as well as CH-2 and CH-3, made it possible to confirm the positioning of the sidechain and of the OH in C2 and C3, respectively. In the NOESY spectrum, an absence of correlation between CH₃-19 and CH-8 suggests the presence of the chain on the β side of the steroid, while a correlation between CH-3 and CH₂-2'/CH₂-6' indicated the β orientation of H-3 and, consequently, an α orientation for the 3-OH. The NMR analysis therefore confirmed the 2 β -R/3 α -OH configuration, as predicted by theory [11,12]. For compound 2 (4 β -R/3 α -OH; Figure 5B), the COSY spectrum showed correlations between CH-4 and CH-5, as well as CH-4 and CH-3. In the NOESY spectrum, no correlation was observed between CH₃-19

and CH-4, suggesting the presence of the sidechain on 4 β -steroid face. On the other hand, three correlations between CH-4 and CH-5, CH-4 and CH-3, CH-4 and CH₂-2'/CH₂-6', as well as CH-3 β and CH₂-2'/CH₂-6' in the NOESY spectrum confirmed the obtention of the 4 β -R/3 α -OH configuration as predicted by the trans-diaxial opening of 3 α ,4 α -epoxide. As for compounds **1** and **2**, the two compounds with a 4 β and 2 β sidechain, respectively, no correlation was observed in the NOESY spectra between the piperazine protons of the sidechain and the axial CH₃-19. These two results could be explained by a conformation of the piperazine nucleus which moves the CH₂-2'/CH₂-6' and CH₂-3'/CH₂-5' away from the CH₃-19.

For compound **3** (2 α -R/3 α -OH; Figure 5C), two J_{HH} correlations between CH-2 and CH₂-1', as well as CH-2 and CH-3 are observed in the COSY spectrum. In addition, in the NOESY spectrum, a correlation between CH₃-19 and CH-2 demonstrated the 2 α orientation (equatorial) of the chain while another correlation between CH-2 β and CH-3 confirms the presence of OH at 3 α (axial). Finally, for compound **4** (3 α -R/2 β -OH; Figure 5D), a J_{HH} correlation between the CH carrying an OH group and CH₂-1' confirms the positioning of OH on C-2, unlike compounds 1–3. A J_{HH} correlation between CH-2 and CH-3 then demonstrates the positioning of the chain on C-3. Since any correlation was observed between CH₃-19 and CH-2 in the NOESY spectrum, the OH is therefore in 2 α -orientation. On the other hand, a correlation in the NOESY spectrum was observed between CH-2 α and CH₂-2'/CH₂-6' supporting a 3 α orientation of the sidechain, which would agree with a trans-diaxial opening of the 2 β ,3 β -epoxide **9**. This 3 α -sidechain orientation is also confirmed by a NOE correlation between CH₂-2'/CH₂-6' of the piperazine nucleus and H-4 α located on the α side of the steroid nucleus. H-4 α had previously been differentiated from H-4 β , which showed an NOE correlation with CH₃-19.




Figure 5. Key correlations observed in NMR experiments and confirming the positioning and orientation (α or β) of the two substituents (sidechain and OH) on steroid A-ring of compounds 1–4 (A–D). Nuclear Overhauser effect (NOE) correlations from NOESY spectra are reported by plain arrows and J_{HH} correlations from COSY spectra are reported by dashed arrows.

2.3. Inhibition of HL-60 Cell Proliferation

Aminosteroids were tested to evaluate their effect on human myeloid leukemia HL-60 cell growth. The assay was performed at a concentration of 10 μ M and the results are expressed as the percentage of cell growth inhibition (Table 2). Interesting SAR results were obtained, since the antiproliferative activity varies depending on the positioning, as well as the orientation of the chain and the OH group present in the steroid A-ring. In fact, the 2 β -R/3 α -OH orientation of compound **1** generates a better cell proliferation inhibition (84%) than those of aminosteroids 2–4. In contrast, the antiproliferative activity is completely lost (1%) by the displacement of the chain from position 2 to 4 (compound **2**; 4 β -R/3 α -OH). Inverting the chain at position 2 with alpha configuration (compound **3**; 2 α -R/3 α -OH) halves the antiproliferative activity (42% vs. 84%). Finally, when the chain is positioned in 3 α and the OH in 2 β (compound **4**), the activity is reduced to 51%. It can be assumed that the diaxial orientation of compound **1** promotes the formation of hydrophobic interactions between a section of the alkyl group and a suspected hydrophobic pocket of the protein targeted by this family of aminosteroids whose exact mechanism of action is not yet fully elucidated. On the other hand, the chair form of the piperazine

ring at C4 seems to move the alkyl group away from the hydrophobic pocket, eliminating all favorable interactions. We also note that the equatorial positioning of the C2 chain (*vs* axial) decreases the activity, but the flexibility of the nonanoyl group seems to maintain several favorable interactions. For compound **4**, it is interesting to note that a rotation of 180° around the longitudinal axis of the steroid (Table 2) allows a diaxial positioning and orientation similar to compound **1**, which could explain that despite a C3 α chain (or pseudo C2 β) and an OH in C2 β (or pseudo C3 α) interactions with the hydrophobic pocket are not fully lost and that it retains an acceptable antiproliferative activity. Either way, it is evident that the 2 β -R/3 α -OH configuration is the one that causes the best inhibition of cancer cell proliferation, and that this diaxial arrangement should be prioritized over other configurations.

Table 2. A-ring substitution and antiproliferative activity (AA).

Compound	1	2	3	4
Structure				
Substitution	2 β -R (axial) 3 α -OH (axial)	4 β -R (axial) 3 α -OH (axial)	2 α -R (equatorial) 3 α -OH (axial)	3 α -R (axial) 2 β -OH (axial)
AA (%) ^a	82	1	42	51

^a Inhibition of the proliferation of leukemia HL-60 cells treated 3 days with compounds **1–4** in comparison to the untreated cells (control). The positive control Doxorubicin inhibited 95% of cell proliferation at 10 μ M.

3. Materials and Methods

3.1. General

Chemical reagents and solvents were purchased from commercial suppliers and used as received. Thin-layer chromatography (TLC) and flash-column chromatography were performed on 0.20-mm silica gel 60 F254 plates (E. Merck; Darmstadt, Germany) and with 230–400 mesh silica gel 60 (Silicycle, Quebec, QC, Canada), respectively. Infrared (IR) spectra were recorded with a Horizon MB 3000 ABB FTIR spectrometer (Quebec, QC, Canada). NMR spectra were recorded at room temperature in CD₃OD with a 5-mm NMR tube on a Bruker AVANCE 400 spectrometer (Billerica, MA, USA). ¹H and ¹³C NMR chemical shifts were referenced to the residual central peak of MeOH (3.33 and 49.0 ppm, respectively). For characterization, we used the following experiments: APT, COSY, NOESY, HSQC, and HMBC. Low-resolution mass spectra (LRMS) were recorded on a Shimadzu Prominence apparatus (Shimadzu Corporation, Kyoto, Japan) equipped with a Shimadzu LCMS-2020 mass spectrometer and an atmospheric-pressure chemical ionization (APCI) probe.

3.2. Synthesis of Compounds **1** and **2**

Aminolysis: A mixture of epoxides **5a** and **5b** in a 76:24 ratio (318 mg, 1.09 mmol), piperazine (2.45 g, 28.5 mmol) and H₂O (2 mL) was refluxed 24 h. The reaction mixture was then cooled, poured into water and the precipitate was filtered. The solid was dissolved in CH₂Cl₂ and the solution dried over Na₂SO₄, filtered, and evaporated to dryness to give a crude mixture of **6a** and **6b** (372 mg). **Amidation:** Under an argon atmosphere at 0 °C, *O*-(benzotriazol-1-yl)-*N,N,N',N'*-tetramethyluronium hexafluorophosphate (HBTU; 358 mg, 0.94 mmol) and nonanoic acid (164.5 mg, 1.04 mmol) were dissolved in dimethylformamide (DMF; 15 mL), diisopropylethylamine (DIPEA; 244 mg, 1.89 mmol) was added and the mixture allowed to react for 5 min. Thereafter, the mixture of **6a** and **6b** (356 mg, 0.94 mmol) dissolved in DMF (20 mL) was added and the temperature was raised to room temperature for 4 h. The reaction mixture was concentrated, and water was added before extraction

with diethyl ether. The organic phase was washed with water, dried over Na_2SO_4 , filtered, and evaporated under reduced pressure. Purification by flash-column chromatography with a gradient of CH_2Cl_2 :MeOH (100:0) to CH_2Cl_2 :MeOH (98:2) yielded the desired amides **1** (98.6 mg, 18% corrected yield for 2 steps) and **2** (53.6 mg, 9.9% corrected yield for 2 steps). 2 β -(4-nonanoylpiperazinyl-5 α -androstane-3 α ,17 β -diol (**1**); IR (film): 3406 (OH), 2925, 2854, 1628 (NC = O), 1445, 1248, 1023 cm^{-1} ; ^1H NMR (400 MHz) and ^{13}C NMR (100.6 MHz) in CD_3OD : data reported in Table 1. LRMS for $\text{C}_{32}\text{H}_{57}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 517.4 (calc) and 517.5 (found) m/z . 4 β -(4-nonanoylpiperazinyl-5 α -androstane-3 α ,17 β -diol (**2**); IR (film): 3406 (OH), 2925, 2854, 1627 (NC = O), 1445, 1245, 1027 cm^{-1} ; ^1H NMR (400 MHz) and ^{13}C NMR (100.6 MHz) in CD_3OD : data reported in Table 1. LRMS for $\text{C}_{32}\text{H}_{57}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 517.4 (calc) and 517.5 (found) m/z .

3.3. Synthesis of Compound 3

Oxidation: Under an argon atmosphere, DMSO (1.29 g, 16.0 mmol) in anhydrous CH_2Cl_2 (1.5 mL) was added dropwise to a solution of oxalyl chloride (1.01 g, 8.0 mmol) in anhydrous CH_2Cl_2 (1.5 mL) at 60 $^\circ\text{C}$. This solution was added dropwise to a solution of compound **1** (343 mg, 0.66 mmol) in anhydrous CH_2Cl_2 (7 mL) to -60 $^\circ\text{C}$ and the reaction mixture was warmed to -20 $^\circ\text{C}$. The mixture was left to react for 30 min, trimethylamine (TEA) (1.61 g, 16.0 mmol) was added, and the mixture was warmed to 0 $^\circ\text{C}$ and left to react 15 min. A saturated solution of NaHCO_3 was added before extraction with CH_2Cl_2 , the organic layer was filtered and evaporated under reduced pressure. The crude compound was purified by flash-column chromatography using a gradient of hexanes/acetone (9:1 to 7:3) to give the 3,17-diketone **7** (151 mg, 44% yield). Reduction: To a solution of **7** (118 mg, 0.23 mmol) in MeOH/ CH_2Cl_2 (9:1) (30 mL) was added NaBH_4 (18 mg, 0.46 mmol) and the mixture was stirred under inert atmosphere at 0 $^\circ\text{C}$. After 1 h, solvents were evaporated, water was added, and the mixture extracted with EtOAc. The organic layer was dried with MgSO_4 , filtered, and evaporated under reduced pressure. The crude compound was purified by flash-column chromatography with CH_2Cl_2 /MeOH (98:2) to give the amide **3** (26 mg, 22% yield). 2 α -(4-nonanoylpiperazinyl-5 α -androstane-3 α ,17 β -diol (**3**); IR (film): 3418 (OH), 2925, 2853, 1633 (NC = O), 1445, 1242, 1051 cm^{-1} ; ^1H NMR (400 MHz) and ^{13}C NMR (100.6 MHz) in CD_3OD : data reported in Table 1. LRMS for $\text{C}_{32}\text{H}_{57}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 517.4 (calc) and 517.4 (found) m/z .

3.4. Synthesis of Compound 4

Aminolysis: The epoxide **8** (70 mg, 0.24 mmol), piperazine (540 mg, 6.26 mmol) and H_2O (1 mL) were refluxed 24 h. The reaction mixture was then cooled, poured in water, and extracted with CH_2Cl_2 . The organic layer was dried with Na_2SO_4 , filtered, and evaporated under reduced pressure to give the desired piperazine derivative **9** (84 mg). Amidation: Under an argon atmosphere at 0 $^\circ\text{C}$, HBTU (74 mg, 0.19 mmol) and nonanoic acid (34 mg, 0.22 mmol) were dissolved in DMF (7 mL), DIPEA (50 mg, 0.39 mmol) was added and the mixture allowed to react for 5 min. Thereafter, the crude aminoalcohol **9** (73 mg, 0.19 mmol) dissolved in DMF (17 mL) was added and the temperature was raised to room temperature for 3 h. The resulting mixture was diluted in water and extracted with CH_2Cl_2 . The organic layer was washed, filtered, and evaporated under reduced pressure. Purification of the crude product by flash chromatography with CH_2Cl_2 :MeOH (100:0) to CH_2Cl_2 :MeOH (98:2) yielded the amide **4** (24 mg, 22% corrected yield for 2 steps). 3 α -(4-nonanoylpiperazinyl-5 α -androstane-2 β ,17 β -diol (**4**); IR (film): 3410 (OH), 2926, 2853, 1628 (NC = O), 1444, 1242, 1024 cm^{-1} ; ^1H NMR (400 MHz) and ^{13}C NMR (100.6 MHz) in CD_3OD : data reported in Table 1. LRMS for $\text{C}_{32}\text{H}_{57}\text{N}_2\text{O}_3$ [$\text{M} + \text{H}$] $^+$: 517.4 (calc) and 517.4 (found) m/z .

3.5. Cell Proliferation Assay

Human promyelocytic leukemia cells HL-60 (ATCC, Rockville, MD, USA) were routinely grown in suspension in 90% RPMI-1640 (Sigma, St. Louis, MO, USA) containing

L-glutamine (2 nM), antibiotics (100 IU penicillin/mL, 100 µg streptomycin/mL) and supplemented with 10% (v/v) foetal bovine serum (FBS), in a 5% CO₂ humidified atmosphere at 37 °C. Cells were maintained twice a week by diluting the cells in RPMI 1640 medium containing 10% FBS. The cell proliferation assay was performed using 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) (Cell Titer 96 Aqueous, Promega, Madison, WI, USA), which allowed us to measure the number of viable cells. In brief, triplicate cultures of 1×10^4 cells in a total of 100 µL medium in 96-well microtiter plates (Becton Dickinson and Company, Lincoln Park, NJ, USA) were incubated at 37 °C, 5% CO₂. Compounds were dissolved in ethanol to prepare the stock solution of 1×10^{-2} M. These compounds and doxorubicin (Novapharm, Toronto, ON, Canada) were diluted at multiple concentrations with culture media, added to each well and incubated for 3 days. Following each treatment, MTS (20 µL) was added to each well and incubated for 4 h. MTS is converted to water-soluble colored formazan by a dehydrogenase enzyme present in metabolically active cells. Subsequently, the plates were read at 490 nm using a microplate reader (Molecular Devices, Sunnyvale, CA, USA).

4. Conclusions

Our previous structure–activity relationship study had only focused on steroid position 2β as well as on sidechain composition. Although interesting results had been obtained at this position, from which certain compounds more active than compound **1** were subsequently identified, it was crucial to explore other sidechain positions and orientations by testing new compounds. After we synthesized compounds **1–4**, a careful ¹H and ¹³C NMR analysis using NOESY, COSY, HSQC, and HMBC experiments was necessary to confirm the right positioning and stereochemistry of the sidechain at C2, C3, or C4, as well as the OH at C3 or C2. The ¹³C and ¹H chemical shifts of the B-, C-, and D-rings did not show any differences between compounds **1–4**, but some A-ring signals were more characteristic and turned out to be good NMR markers. Thus, the identical chemical shifts of CH-2 and 3 (66.5 ppm) make it possible to differentiate compound **1** (2β-R/3α-OH) from the others. For compound **2** (4β-R/3α-OH), positioning the chain in position 4 causes a significant deshielding effect for CH-4 (70.5 vs. 63.0–66.5 ppm) and CH-5 (45.7 vs. 40.0–41.1 ppm). For compound **3** (2α-R/3α-OH), reversing the orientation of the chain at position 2 causes a shielding effect of 3.5 ppm for CH-2, but particularly affects CH₃-19. Indeed, a shielding effect makes it possible to differentiate it from other compounds as much in ¹³C NMR (12.9 vs. 14.5–15.6 ppm) as in ¹H NMR 0.86 vs. 1.04–1.11 ppm). Finally, two markers are assigned to compound **4** (3α-R/2β-OH), i.e., 42.4 (CH₂-1) and 15.6 (CH₃-19) ppm.

Through NMR analysis, it was then possible to validate which of the four chain configurations and OH in the A-ring of compounds **1–4** was most important for antileukemia activity. As demonstrated with a viability cell assay with the HL-60 cancer cell line, the 2β-R/3α-OH configuration of compound **1** was shown to be the most advantageous among the four configurations.

Supplementary Materials: The following are available online at <https://www.mdpi.com/2312-7481/7/1/3/s1>, ¹H NMR, ¹³C NMR (APT), NOESY, COSY, HSQC, and HMBC spectra for compounds **1–4**. They are available online at www.mdpi.com/link.

Author Contributions: D.P. analyzed the NMR data and wrote the paper; I.R. performed chemical synthesis; J.R. tested the compounds; R.M. analyzed the NMR data; R.M. collaborated on the chemical synthesis and revised the paper. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by the Canadian Institutes of Health Research grant number DDP-82934.

Acknowledgments: We are grateful to Marie-Claude Trottier for NMR spectra and to Micheline Harvey for careful reading of this manuscript.

Conflicts of Interest: D.P., J.R. and R.M. have patent rights on US8653054 and CA2,744,369 (2-(N-Substituted piperaziny) steroid derivatives).

References

1. He, Q.; Na, X. The effects and mechanisms of a novel 2-aminosteroid on murine WEHI-3B leukemia cells in vitro and in vivo. *Leukemia Res.* **2001**, *25*, 455–461. [[CrossRef](#)]
2. Thibeault, D.; Roy, J.; DeRoy, P.; Poirier, D. Chemical synthesis of 2 β -amino-5 α -androstane-3 α ,17 β -diol N-derivatives and their antiproliferative effect on HL-60 human leukemia cells. *Bioorg. Med. Chem.* **2008**, *16*, 5062–5077. [[CrossRef](#)] [[PubMed](#)]
3. Roy, J.; Maltais, R.; Jegham, H.; Poirier, D. Libraries of 2 β -(N-substituted piperazino)-5 α -androstane-3 α ,17 β -diols: Chemical synthesis and cytotoxic effects on human leukemia HL-60 cells and on normal lymphocytes. *Mol. Divers.* **2011**, *15*, 317–339. [[CrossRef](#)] [[PubMed](#)]
4. Ayan, D.; Maltais, R.; Hospital, A.; Poirier, D. Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5 α -androstane-3 α ,17 β -diol derivatives. *Bioorg. Med. Chem.* **2014**, *22*, 5847–5859. [[CrossRef](#)] [[PubMed](#)]
5. Gupta, A.; Kumar, B.S.; Negi, A.S. Current status on development of steroids as anticancer agents. *J. Steroid Biochem. Mol. Biol.* **2013**, *137*, 242–270. [[CrossRef](#)] [[PubMed](#)]
6. Jegham, H.; Maltais, R.; Roy, J.; Doillon, C.; Poirier, D. Biological evaluation of a new family of aminosteroids that display a selective toxicity for various malignant cell lines. *Anti-Cancer Drugs* **2012**, *23*, 803–814. [[CrossRef](#)] [[PubMed](#)]
7. Kenmogne, L.C.; Ayan, D.; Roy, J.; Maltais, R.; Poirier, D. The aminosteroid derivative RM-133 shows in vitro and in vivo antitumor activity in human ovarian and pancreatic cancers. *PLoS ONE* **2015**, *10*, e0144890. [[CrossRef](#)] [[PubMed](#)]
8. Maltais, R.; Hospital, A.; Delhomme, A.; Roy, J.; Poirier, D. Chemical synthesis, NMR analysis and evaluation on a cancer xenograft model (HL-60) of the aminosteroid derivative RM-133. *Steroids* **2014**, *82*, 68–76. [[CrossRef](#)] [[PubMed](#)]
9. Roy, J.; DeRoy, P.; Poirier, D. 2 β -(N-substituted piperazino)-5 α -androstane-3 α ,17 β -diols: Parallel solid-phase synthesis and antiproliferative activity on human leukemia HL-60 cells. *J. Comb. Chem.* **2007**, *9*, 347–358. [[CrossRef](#)] [[PubMed](#)]
10. Thibeault, D.; Poirier, D. An efficient method for the regioselective aminolysis of 2,3 α -steroidal epoxyde. *Synlett* **2003**, *8*, 1192–1194.
11. Barton, D.H.R. The stereochemistry of cyclohexane derivatives. *J. Chem. Soc.* **1953**, 1027–1040. [[CrossRef](#)]
12. Matthews, G.J.; Hassner, A. *Organic Reactions in Organic Chemistry*; Fried, J., Edwards, J.A., Eds.; Van Nostrand Reinhold Company: New York, NY, USA, 1972; Volume 2, pp. 1–53.
13. Anderson, A.; Boyd, A.C.; Byford, A.; Campbell, A.C.; Gemmill, D.K.; Hamilton, N.M.; Hill, D.R.; Hill-Venning, C.; Lambert, J.J.; Maidment, M.S.; et al. Anesthetic activity of novel water-soluble 2 β -morpholinyl steroids and their modulatory effects at GABA_A receptors. *J. Med. Chem.* **1997**, *40*, 1668–1681. [[CrossRef](#)]
14. He, Q.; Xu, Y.H. Synthesis of 2 β -(4'-methyl-1'-piperazino)-3 α -hydroxyl-16,17-substituted-5 α -androstanes. *Acta Pharm Sin.* **1992**, *27*, 101–106.
15. Lewett, C.L.; Savage, D.S. Amino-steroids. Part III.¹ 2- and 3-Amino-5 α -androstanes. *J. Chem. Soc.* **1968**, 1134–1140. [[CrossRef](#)]
16. Mancuso, A.J.; Huang, S.L.; Swern, D. Oxidation of long-chain and related alcohols to carbonyls by dimethylsulfoxide "activated" by oxalyl chloride. *J. Org. Chem.* **1978**, *43*, 2480–2482. [[CrossRef](#)]
17. Cadot, C.; Laplante, Y.; Kamal, F.; Luu-The, V.; Poirier, D. C6-(N,N-butyl-methyl-heptanamide) derivatives of estrone and estradiol as inhibitors of type 1 17 β -hydroxysteroid dehydrogenase: Chemical synthesis and biological evaluation. *Bioorg. Med. Chem.* **2007**, *15*, 714–726. [[CrossRef](#)] [[PubMed](#)]
18. Blunt, J.W.; Stothers, J.B. ¹³C N.m.r. spectra of steroids—A survey and commentary. *J. Magn. Reson.* **1977**, *9*, 439–464. [[CrossRef](#)]
19. Poirier, D.; Maltais, R. NMR-assisted structure elucidation of an anticancer steroid- β -enaminone derivative. *Magnetochemistry* **2017**, *3*, 37. [[CrossRef](#)]
20. Tchédam-Ngatcha, B.; Trottier, M.C.; Poirier, D. ¹³C Nuclear magnetic resonance spectroscopy data of a variety of androsterone and epi-androsterone derivatives substituted at position 3 β or/and 3 α . *Curr. Top. Steroid Res.* **2011**, *8*, 35–46.
21. Fielding, L. ¹H and ¹³C NMR studies of some steroidal neuromuscular blocking drugs: Solution conformations and dynamics. *Magn. Reson. Chem.* **1998**, *36*, 387–397. [[CrossRef](#)]